Teriflunomide Observational Effectiveness Study
Teriflunomide Observational Effectiveness Study
The main goal of this investigator-initiated study is to evaluate the effectiveness and
 efficacy of Teriflunomide in a population of Relapsing Remitting Multiple Sclerosis (RRMS)
 patients treated in regular practice, over a period of at least two years, in the regular
 setting of a Multiple Sclerosis Clinic.
Consenting adult RRMS patients, meeting all inclusion criteria and who have been prescribed
 Teriflunomide by their treating physician will be asked to complete questionnaires on quality
 of life (QoL), fatigue, and employment.

 The study will include 300 participants from three Multiple Sclerosis (MS) Clinics. Disease
 and magnetic resonance imaging (MRI) activity, blood tests (aspartate aminotransferase (AST),
 alanine aminotransferase (ALT), complete blood count (CBC)), drug compliance, side effects,
 toxicity, will be monitored.

 MS patients never treated with a disease modifying drug (DMD) and MS patients previously
 exposed to another DMD will be included. Some would have been on a single medication, while
 others would have been treated with two or more medications.

 The results of the study will provide the patient-perceived global impacts of Teriflunomide
 on the patient's overall quality of life.

 These results will also guide the physician in giving a treatment that will be adapted to the
 patient's major concerns.
Inclusion Criteria:

 -  Consenting Relapsing Remitting Multiple Sclerosis adults with an Expanded Disability
 Status Scale (EDSS) score ≤ 5.0 who have been prescribed Teriflunomide and who agree
 to follow study procedures.

 Exclusion Criteria:

 -  Primary progressive or secondary progressive Multiple Sclerosis without relapses;
 other diseases that may confound evaluation of outcomes; other exclusion as per
 product monograph; and women contemplating pregnancy or actually pregnant.